Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), Canada’s most innovative cannabis extractor, is pleased to provide shareholders with the following commercial update:

Vape Cartridges Powered by OILSTM now Available in the Provincial Retail Market


Vape cartridges powered by OILS high purity distillate are available at cannabis retailers in the Saskatchewan adult-use market, with more provinces to be announced in the coming months. The launch of vape cartridges into provincial retail through the Company’s Commercial Partners Program represents an important milestone for OILS in the commercialization of its intellectual property (“IP“) portfolio.

“This represents the first step in OILS entering the adult-use market in a meaningful way. We look forward to a sequence of product launches in the months ahead, as Nextleaf supports the launch of innovative cannabis products through its Commercial Partners Program,” said Nextleaf CEO Paul Pedersen.

Commercial and Supply Update

The Company, through its wholly owned subsidiary Nextleaf Labs Ltd. (“Nextleaf Labs“), completed the bulk sale of premium tetrahydrocannabinol (THC) distillate to a British Columbia (BC)-based licensed cannabis processor focused on the manufacturing and distribution of branded cannabis consumer products through provincial retail.

Additionally, Nextleaf is pleased to announce the Company has entered into a bulk cannabis distillate supply agreement (the “Sales Agreement“) with a BC-based licensed processor and one of Canada’s top selling cannabis brands (the “Client“). Pursuant to the Sales Agreement, Nextleaf will supply over 100 kilograms of cannabidiol (CBD) distillate to the Client for the purposes of manufacturing white label CBD based products.

“We see this as the beginning of a long-term relationship with a cannabis brand that does some of the highest sales volume in Canada,” stated Nextleaf CFO Charles Ackerman.

Nextleaf has entered into a bulk cannabis biomass supply agreement (the “Supply Agreement“) whereby the Client supplies over 2,000 kilograms of THC and CBD cannabis biomass for Nextleaf Labs to process into distilled THC and CBD oils using Nextleaf’s patented extraction platform.

Since commencing commercial oil production earlier this year, Nextleaf has contracted supply of over 27,000 kilograms of dried cannabis biomass from licensed cultivators through the OILS Commercial Partners Program. Pursuant to the program, Nextleaf Labs efficiently toll processes cannabis biomass into distilled THC and CBD oils, and sells the resulting bulk cannabinoids through Nextleaf’s Commercial Partners and the Canadian wholesale market.

“We believe our investment in IP and our existing fixed asset base will help OILS ensure the long-term sustainability of our business, provide a robust platform to scale, and a clear competitive advantage to provide high quality cannabinoids produced through Nextleaf’s ultra-efficient cannabis oil refinery,” Ackerman concluded.

Research and Development

Nextleaf continues to bolster its IP portfolio by commencing trials of its proprietary pesticide remediation process with the goal of solving the industry’s prevalent pesticide drift challenge. The current contamination struggles experienced by licensed cultivators growing in repurposed greenhouses and outdoor fields is being magnified when cannabis and hemp biomass is processed into concentrated oils. The Company hopes to provide its clients with a viable scaled solution next year and believes the proprietary technology will have significant commercial value in other jurisdictions that require legal cannabis products to be tested for banned pesticides.

With increased production of cannabis 2.0 products across Canada, product differentiation has become paramount for producers as they compete for market share. Nextleaf plans to begin offering sensory and palatability trials under Nextleaf Labs’ existing Research licence upon Health Canada approving the licence amendment, as an additional value-added B2B service.

Nextleaf is developing IP around unique formulations and delivery methods of THC and CBD. The Company increased its R&D efforts focused on commercializing a THC powder format of its Rapid Emulsion Technology by OILS™. With dissolvable THC powder outselling most ready to drink infused beverages in Canada, Nextleaf is preparing to launch its patent pending rapid emulsion technology in THC drops and dissolvable powder formats.

Nextleaf Receives 50th Issued Patent

The United States Patent and Trademark Office has granted OILS a patent for the formulation of a solventless extract. In provinces where vape cartridges cannot be sold, solventless extracts are the top selling concentrate product. This patent continues Nextleaf’s success rate of 100% pending to issued patents and marks the 50th issued patent for the extraction, purification, and delivery of cannabinoids. The Company has been issued patents in the key markets of the United States, Canada, Israel, Australia, New Zealand, Colombia, South Africa, and across the European Union.

“I’m extremely proud of our team for receiving its 50th issued patent, which represents the second largest patent portfolio of any cannabis company,” said Paul Pedersen, CEO of Nextleaf Solutions.

About Nextleaf®

OILS is Canada’s most innovative cannabis extractor, developing technology for extracting and distilling cannabinoids. OILS provides extraction services and wholesale of THC and CBD oils through its wholly owned subsidiary Nextleaf Labs Ltd., a Health Canada licensed standard processor. Nextleaf’s proprietary closed-loop extraction plant in Metro Vancouver has a design capacity to process 600 kg per day of dried cannabis biomass into distilled oils. OILS is the first public company to be issued U.S. patents for industrial-scale extraction and distillation of cannabinoids. The Company owns a portfolio of 50 issued patents and over 55 pending patents for the extraction, purification, and delivery of cannabinoids.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow OILS across social media platforms: Twitter, LinkedIn, Facebook, and Instagram.

www.nextleafsolutions.com

For more information please contact:
Jason McBride
604-283-2301 (ext. 219)
investors@nextleafsolutions.com

On behalf of the Board of Directors of OILS,

Paul Pedersen, CEO

Certain statements contained in this press release constitute “forward-looking statements”. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company’s ability to capitalize on its IP portfolio, the Company’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66828

News Provided by Newsfile via QuoteMedia

  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less